Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease

Journal of Neurochemistry

Volumn 80, Issue 2, 2002, Pages 262-270

  Ikeda, Ken ^a   Kurokawa, Masako ^a   Aoyama, Shiro ^a   Kuwana, Yoshihisa ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

6 Hydroxydopamine (6 OHDA); Adenosine A2A receptor; KW 6002; MPTP; Neuroprotection; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,3 DIMETHYL 8 (3,4,5 TRIMETHOXYSTYRYL) 7 METHYL 3,7 DIHYDRO 1H PURINE 2,6 DIONE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 8 DICYCLOPROPYLMETHYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2 RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ISTRADEFYLLINE; KF 18446; NEUROTOXIN; OXIDOPAMINE; UNCLASSIFIED DRUG; 1 METHYL 4 PHENYLPYRIDINIUM; ADENOSINE A2A RECEPTOR; ADENOSINE RECEPTOR; ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HERBICIDE; NEUROPROTECTIVE AGENT; PURINE DERIVATIVE; TRITIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CELL LOSS; CELL VACUOLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GLIOSIS; LONG TERM CARE; MALE; MONKEY; MOTOR CONTROL; NEUROPROTECTION; NEWBORN; NONHUMAN; PALLIATIVE THERAPY; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BLOCKING; ANIMAL; CELL STRAIN; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; NERVE CELL; NERVE DEGENERATION; PARKINSONISM; SPRAGUE DAWLEY RAT;

ANIMALIA; PARKINSONIA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE AGENTS; GLIOSIS; HERBICIDES; MALE; NERVE DEGENERATION; NEURONS; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PC12 CELLS; PURINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ADENOSINE A2A; RECEPTORS, PURINERGIC P1; SYMPATHOLYTICS; TRITIUM;

EID: 0036020950     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-3042.2001.00694.x     Document Type: Article

References (48)

1. Rescue of locomotor impairment in dopamine D2 receptor deficient mice by an adenosine A2A receptor antagonist
2. Vesicular acetylcholine transporter (VAChT) protein: A novel and unique marker for cholinergic neurons in the central and peripheral nervous systems
3. Acute effects of 1-methyl-1,4-phenylpyridinium ion (MPP+) on purine metabolism in the rat striatum studied in vivo using the microdialysis technique
4. Selective attenuation of psychostimulant-induced behavioral responses in mice lacking A2A adenosine receptors
5. Neuroprotection by caffeine and A2A adenosine receptor inactivation in model of Parkinson's disease
6. Acute ultrastructural effects of MPTP on the nigrostriatal pathway of the C57BL/6 adult mouse: Evidence of compensatory plasticity in nigrostriatal neurons
7. Prospects for new restorative and neuroprotective treatments in Parkinson's disease
8. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors
9. Amplification of the cyclic AMP response to forskolin in pheochromocytoma PC12 cells through adenosine A (2A) purinoceptors
10. Nomenclature and classification of purinoceptors
11. Grial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease
12. 11C-Labeled KF18446: A potential central nervous system adenosine A2a receptor ligand
13. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys
14. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets
15. Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys
16. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity
17. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-Parkinsonian rats
18. Adenosine A2a receptor-mediated modulation of striatal acetylcholine release in vivo
19. In vivo regulation of acetylcholine release via adenosine A1 receptor in rat cerebral cortex
20. Antiparkinsonian activity of adenosine A2A antagonists in experimental models
21. A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter
22. Membrane trafficking of neurotransmitter transporters in the regulation of synaptic transmission
23. Distinct mechanisms underlie neurotoxin mediated cell death in cultured dopaminergic neurons
24. Fluctuations in disability in Parkinson's disease: Clinical aspects
25. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration to C57-black mice leads to parallel decrements in neostriatal dopamine content and tyrosine hydroxylase activity
26. Adenosine prevents the death of mesencephalic dopaminergic neurons by a mechanism that involves astrocytes
27. Genetic and environmental factors in the pathogenesis of Parkinson's disease
28. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons
29. Effects of protein kinase inhibitors and protein phosphatase inhibitors on cyclic pheochromocytoma PC12
30. KF17837 (E)-8-(3,4-dimethoxystyryl)-1,3-dipropyl-7-methylxanthine), a potent and selective adenosine A2 receptor antagonist
31. 3H] KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membrane
32. Systemic administration of adenosine A2A receptor antagonist reverses increased GABA release in the globus pallidus of unilateral 6-hydroxydopamine-lesioned rats: A microdialysis study
33. Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum
34. Selective A2A adenosine receptor activation reduces ischemia-reperfusion injury in rat kidney
35. Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats
36. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine
37. Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease
38. Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: A target for neuroprotection
39. A cloned G protein-coupled protein with a distribution restricted to striatal medium-sized neurons. Possible relationship with D1 dopamine receptor
40. Adenosine A2A antagonists with potent anti-cataleptic activity
41. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP
42. Effects of adenosine receptors
43. Neutrophil A2A adenosine receptor inhibits inflammation in a rat model of meningitis: Synergy with the type IV phosphodiesterase inhibitor, rolipram
44. Time course of MPTP-induced degeneration of the nigrostriatal dopamine system in C57BL/6 mice
45. Distribution, biochemistry and function of striatal adenosine A2A receptors
46. Vesicular neurotransmitter transporter
47. Simultaneous determination of norepinephrine, dopamine, 5-hydroxytryptamine and their main metabolites in rat brain using high-performance liquid chromatography with electrochemical detection. Enzymatic hydrolysis of metabolites prior to chromatography